Diseases, Conditions, Syndromes

MERS-CoV treatment effective in monkeys, study finds

Treatment with two common drugs reduced viral replication and lung damage when given to monkeys infected with the virus that causes Middle East Respiratory Syndrome. The condition is deadly pneumonia that has killed more ...

Diseases, Conditions, Syndromes

Active substance raises hopes of curing hepatitis E

An international team of researchers has now found a possible active substance against the virus in the naturally occurring substance silvestrol. The substance inhibited the replication of pathogens both in cell culture and ...

Cardiology

Probable interaction ID'd for PrOD, ribavirin with warfarin

(HealthDay)—There is a probable interaction between paritaprevir/ritonavir/ombitasvir+dasabuvir (PrOD) plus ribavirin with warfarin, according to a case report published online Nov. 3 in the Journal of Clinical Pharmacy ...

Diseases, Conditions, Syndromes

Antiviral favipiravir successfully treats Lassa virus in guinea pigs

Favipiravir, an investigational antiviral drug currently being tested in West Africa as a treatment for Ebola virus disease, effectively treated Lassa virus infection in guinea pigs, according to a new study from National ...

Diseases, Conditions, Syndromes

FDA approves technivie for hepatitis C

(HealthDay)—Technivie (ombitasvir, paritaprevir and ritonavir) has been approved by the U.S. Food and Drug Administration, in tandem with ribavirin, to treat hepatitis C genotype 4 infection among people without cirrhosis ...

Diseases, Conditions, Syndromes

Sofosbuvir plus ledipasvir seems effective for HCV genotype 1

(HealthDay)—For patients with chronic hepatitis C virus genotype 1 (HCV GT-1) infection who are ineligible for interferon therapy, and who relapsed after sofosbuvir and ribavirin treatment, sofosbuvir plus ledipasvir is ...

Diseases, Conditions, Syndromes

Predicting hepatitis C treatment success

Levels of interferon-stimulated genes in the liver and blood could help predict if a patient with hepatitis C will respond to conventional therapy, researchers at Kanazawa University suggest.

page 1 from 4